ストックスクリーナーアプリを入手
0.00
100.00%
-11.13
前日終値:
$11.13
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$994.04M
収益：
$20.65M
当期純損益:
$-192.65M
株価収益率:
0.00
EPS:
-2.59
ネットキャッシュフロー:
$-134.39M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
VERV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
0.00 | 994.04M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-10-06 | 開始されました | Credit Suisse | Neutral |
| 2022-08-25 | アップグレード | Stifel | Hold → Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-24 | 開始されました | Stifel | Hold |
| 2021-07-12 | 開始されました | Guggenheim | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Neutral |
| 2021-07-12 | 開始されました | Jefferies | Buy |
| 2021-07-12 | 開始されました | William Blair | Outperform |
すべてを表示
Verve Therapeutics Inc (VERV) 最新ニュース
What insider trading reveals about Verve Therapeutics Inc. stockMarket Trend Report & Stock Portfolio Risk Control - newser.com
Price momentum metrics for Verve Therapeutics Inc. explained2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
Is Verve Therapeutics Inc. stock in correction or buying zoneRate Hike & Entry Point Strategy Guides - newser.com
How resilient is Verve Therapeutics Inc. stock in market downturnsWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
What drives Verve Therapeutics Inc stock pricePrice-to-Earnings Ratio Insights & Rapid Profit Portfolio - earlytimes.in
Automated trading signals detected on Verve Therapeutics Inc.July 2025 Breakouts & Reliable Trade Execution Plans - newser.com
Can Verve Therapeutics Inc. stock withstand economic slowdownWeekly Investment Report & Fast Moving Trade Plans - newser.com
Verve Therapeutics Inc. stock daily chart insightsQuarterly Trade Report & Growth Focused Entry Reports - newser.com
Sector ETF performance correlation with Verve Therapeutics Inc.Rate Cut & Risk Adjusted Buy/Sell Alerts - newser.com
Is Verve Therapeutics Inc. stock entering bullish territoryWeekly Market Outlook & Daily Price Action Insights - newser.com
Is Verve Therapeutics Inc. stock a safe buy before earningsProduct Launch & Verified High Yield Trade Plans - newser.com
How to track smart money flows in Verve Therapeutics Inc.Earnings Overview Summary & Safe Entry Point Identification - newser.com
Will Verve Therapeutics Inc. stock continue dividend increases2025 EndofYear Setup & Risk Managed Investment Entry Signals - Fundação Cultural do Pará
Technical analysis overview for Verve Therapeutics Inc. stockEarnings Recap Summary & AI Driven Stock Movement Reports - newser.com
Has Verve Therapeutics Inc. formed a bullish divergenceGap Up & Entry Point Strategy Guides - newser.com
Will Verve Therapeutics Inc. bounce back from current supportTrade Signal Summary & Safe Capital Allocation Plans - newser.com
How Verve Therapeutics Inc. stock benefits from global expansionMarket Activity Summary & Low Risk High Win Rate Stock Picks - newser.com
Is Verve Therapeutics Inc. stock safe for conservative investorsDividend Hike & Daily Stock Trend Reports - Fundação Cultural do Pará
Verve Therapeutics Inc (VERV) 財務データ
収益
当期純利益
現金流量
EPS
2.13%
4.32%
大文字化:
|
ボリューム (24 時間):